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Introduction: Severe persistent asthma represents a major and costly public health issue.
There is evidence that long-term treatment with omalizumab might have disease-modifying
activity but data on the consequences of discontinuing treatment after a positive response
are limited. The purpose of this study was to investigatedin real-life prescribing conditionsd
what happens when omalizumab is discontinued in patients with severe, persistent allergic
asthma who have responded well to omalizumab treatment.
Methods: An observational, descriptive, cross-sectional, retrospective study to establish the
time to loss of asthma control after the discontinuation of courses of omalizumab treatment
of varying duration.
Results: 24 lung specialists reviewed data from 61 responder patients who had discontinued
omalizumab after a mean duration of 22.7  13.1 [range: 2.5; 59.5] months of treatment. Loss
of asthma control was documented in 34 patients (55.7%) with a median interval between
discontinuation and loss of control of 13.0 months (mean 20.4  2.6 [95% CI: 8.3e28.1]). No
correlation was detected between time to loss of control and duration of treatment, although
control tended to be sustained for longer in patients whose response had been classified as
“excellent” as opposed to “good” (median: 17.0 vs. 12.8 months; NS).
Discussion: The discontinuation of omalizumab was not associated with any rebound effect or
exacerbation of the disease, and control was sustained throughout the follow-up period of at
least 6 months in nearly half of all patients, including all of those who had been treated for 3.5
years ormore. After the reintroduction of omalizumab, 4 out of 20patients did not respond again.
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Asthma remains a major public health problem and a sig-
nificant proportion of patients have severe, persistent dis-
ease that is refractory to continuous treatment, even with
a combination of high-dose inhaled corticosteroids and
long-acting b2-agonists [1]. Although this difficult-to-treat
population represents about 5% of all asthma patients, it
accounts for over half of the high cost of asthmatic disease
to society [2].
Omalizumab, introduced in the United States in 2003 and
in Europe in 2005, has been shown to be highly effective at
preventing clinically significant asthma exacerbations and
reducing steroid requirements in patients with severe,
persistent allergic asthma [3e7], notably in those in whom
best-available treatment has proven inadequate [8e10] and
those at greatest risk of serious morbidity or death [11].
Omalizumab has also been shown to reduce symptoms,
improve lung function and improve asthma-related quality
of life, and to have a good tolerability profile [reviewed in
Ref. [12]].
Omalizumab is a recombinant humanised monoclonal
antibody directed against an epitope on the immunoglob-
ulin E molecule (IgE). Binding of omalizumab to IgE blocks
its interaction with the high-affinity IgE receptor (FCεRI),
which is found on mast cells, basophils and dendritic cells,
and which takes part in Th2 immune response. Treatment
with omalizumab has been shown to down-regulate FcεRI
expression on blood basophils and plasmacytoid dendritic
cells in patients with severe allergic asthma [13], which
might indicate long-term disease-modifying potential.
By June 2013, omalizumab treatment had been initiated
in more than 6000 patients in France. The prescribing in-
formation for omalizumab stipulates that it is “intended for
long-term treatment”, and recommends an evaluation of
treatment effectiveness after 16 weeks to decide whether
or not to continue. However, no guidance is given on when
to discontinue treatment in a responding patient, because,
to date, there have been no data from appropriately
designed clinical trials that would inform such guidance.
Most studies of omalizumab have so far focused on its short-
to medium-term clinical effects, but some biological ob-
servations, such as FcεRI down-regulation [13], suggest that
omalizumab may have disease-modifying activity if treat-
ment is continued for long enough.
The purpose of this study was to investigate, retro-
spectively, the clinical effects of omalizumab discontinua-
tion in a real-life population of patients with severe,
persistent, allergic asthma whose physician had decided to
stop treatment because of good asthma control.
Methods
This was a multicentre, descriptive, observational, retro-
spective study conducted at 24 centres in France. The
objective of the study was to establishdin a real-life pop-
ulation of patients with severe, refractory, allergic asthma
who had been successfully treated with omalizumabdthe
time to loss of asthma control after discontinuation of the
drug. Omalizumab had been effective at establishing con-
trol of the asthma in all of these patients. Good asthmacontrol was based on physicians judgement, who took into
account the absence of exacerbation and OCS use and the
improvement in symptoms, rescue medication use and/or
lung function. Subsequent loss of control was defined as one
of the following: (i) an exacerbation requiring treatment
with an oral corticosteroid (OCS), with failure to re-
establish control within 1 month after the last dose of
OCS; (ii) two exacerbations requiring OCS treatment within
1 year; or (iii) the persistence of guideline-based criteria of
poor control [at least 3 GINA criteria and/or an increase in
Asthma Control Questionnaire (ACQ) score of over 1.5 and/
or an Asthma Control Test (ACT) score of 19 or less] for over
a month.
For this cross-sectional, retrospective study, a randomly
selected sample of French lung specialists who had pre-
scribed omalizumab were asked to identify all patients of
any age and either gender who had been successfully
treated (i.e. resulting in establishment of control of the
disease) with a stable dosage of omalizumab for severe,
persistent, allergic asthma, whose medical records showed
either loss of control at some point after the discontinua-
tion of omalizumab or at least 6 months of sustained control
post-withdrawal.
Data were collected from patients’ medical records
between the beginning of May and the end of October 2011.
To establish how omalizumab is used in everyday practice,
patients’ characteristics were reviewed together with de-
tails of omalizumab treatment. Demographic details (date
of birth, gender, weight, height and BMI) and baseline
asthma characteristics (asthma history, total IgE level,
forced expiratory volume measurements (FEV1) and main-
tenance asthma treatments) were recorded during omali-
zumab treatment. Omalizumab dosage and treatment
duration were analysed. Physicians were asked to provide
data recorded at the date of discontinuation: bodyweight,
FEV1 and maintenance asthma treatments, duration of
satisfactory asthma control, date of the last exacerbation
requiring treatment with an OCS, control criteria used to
make the decision to discontinue omalizumab, and a sub-
jective estimate of the global effectiveness of the course of
omalizumab treatment in each case (“good” or “excel-
lent”). After discontinuation, the date of loss of control,
and the criterion or criteria used to define loss of control,
were recorded. If a patient was restarted on omalizumab,
the physician was asked to provide an estimate of the
global effectiveness of the follow-up course.Statistics
An analysis population was defined, based on main inclu-
sion/exclusion criteria and minimum follow-up duration
availability. Quantitative variables were expressed as mean
and standard deviation, or median and 95% confidence in-
tervals. Qualitative variables were expressed as number of
patients and percentage. Missing data are indicated. Time
to loss of control was calculated using the KaplaneMeier
method. Certain analyses were performed on sub-groups
stratified according to the physician’s estimate of the
global effectiveness of omalizumab treatment and the
length of the course of omalizumab treatment (<1 year,
1e2 years and >2 years).
Table 1 Demographics and asthma characteristics at the
time of the prescription of omalizumab.
Parameter Study population (n Z 61)
Age (mean  SD) [range] 40.7  20.31 [6e82]
6e11 years, n (%) 8 (13.1)
12e17 years, n (%) 6 (9.8)
18 years, n (%) 47 (77.0)
Female, n (%) 40 (65.6)
Bodyweight (mean  SD) (kg) 69.7  22.8
Height (mean  SD) (cm) 161.3  15.5
BMI (mean  SD) (kg/m2) 26.2  6.7
Asthma characteristics
Duration of asthma (years)
Mean  SD [range] MD
22.3  15.7 [2e70] 1
Total IgE (IU/mL)
Mean  SD [range] MD
544  844 [29e5000] 1
<30 IU/mL, n (%) 1 (1.7)
30e700 IU/mL, n (%) 45 (75.0)
700 IU/mL, n (%) 14 (23.3)
FEV1 (mL)
Mean  SD [range]
1962  873 [820e4630]
FEV1 (% predicted)
Mean  SD [range]
72  24 [27e161]
Daily ICS dosage
(mg, BDP equivalent) (n Z 54)
Mean  SD [range] MD
2142  997 [500e4000] 6
BDP, beclomethasone dipropionate; BMI, body mass index; ICS,
inhaled corticosteroid; MD,missing data; SD, standard deviation.
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Patients
A total of 73 patients were identified by 24 physicians.
Twelve of these patients were excluded from the analysis
population, the main reasons being need for OCS at the
time of discontinuation (6 patients) e a patient who still
requires continuous OCS treatment cannot be considered as
well controlled e insufficient follow-up time in patients in
whom loss of control was not documented (2 patients), and
no details on control (2 patients). Therefore, the study
population comprised 61 patients.
Characteristics at the time of omalizumab initiation
Baseline characteristics are shown in Table 1. Patients were
between 6 and 82 years of age (mean 41 years; eight be-
tween 6 and 11 years and six between 12 and 17 years), and
nearly two-thirds were women. All had longstanding severe
asthma (mean duration: 22.3  15.7 years) with constitu-
tively impaired respiratory function (mean FEV1 72% of the
predicted value). Mean IgE level was 544  844 IU/mL. All
patients except one were taking an inhaled corticosteroid
(ICS; 50% fluticasone, 40% budesonide and 10% beclome-
thasone), at a mean beclomethasone-equivalent dosage of
2142 (range: 500e4000) mg per day. All except two were
taking a long-acting b2-agonist, and 7 were taking a main-
tenance OCS (mean dosage 25.6 mg/day; range: 4e60 mg/
day).
Omalizumab treatment and discontinuation
All patients had started omalizumab between June 2003
and January 2010, and had discontinued it between May
2005 and December 2011. The average duration of treat-
ment was 22.7  13.1 months (median: 22.1 months; range
2.5e59.5 months; Table 2), and the duration of satisfactory
on-treatment control of the disease was 15.1  11.8 months
(range 0e56.2 months). Before discontinuation, the mean
time free of exacerbations was 8.7  7.7 months.
The response to omalizumab was considered ‘excellent’
(indicating complete response) in 32 patients (52.5%) and
‘good’ (indicating marked improvement) in the other 29
(47.5%), with particularly good results in the youngest
patients 87.5% of 6e11-year-olds had ‘excellent’ response.
In parallel, 45 patients (73.8%) reported improvement in
comorbid allergic disorders (including perennial rhinitis,
seasonal allergic rhinitis, conjunctivitis and sinusitis).
At the time of discontinuation, physicians were asked to
provide asthma control criteria used to justify the decision
to discontinue omalizumab treatment: absence of any
exacerbation and no need of any OCS were mentioned first;
96.7% and 82% respectively. All physicians had documented
at least one asthma control criteria: no exacerbation, no
OCS, lung function improvement, daytime and/or nocturnal
symptoms improvement, no limitation of activities, no need
for rescue treatment, and/or ACT/ACQ. Asthma Control
Test was recorded for 22 patients (36.1%). Although most
patients (95.1%) were still using ICSs at the time of
discontinuation, the mean dosage had decreased by about13% compared with baseline. Also at discontinuation, no
patients were using an OCS (this was an exclusion crite-
rion). 3 patients had discontinued long-acting b2-agonist
therapy (although 91.8% were still taking one). The respi-
ratory function was improved with an average increase of
343 mL (þ13% of the predicted value).
Time to loss of control
After discontinuation, the median follow-up time (i.e.
either time to loss of control or the period between
discontinuation of omalizumab and the last date on which
data were available for a patient with sustained control)
was 9.3 months (mean: 12.1  9.8 [95% CI: 9.6e14.5]). Loss
of asthma control was documented in 34 (55.7%) patients
(Table 3): 26 (55.3%) of those who were adults at the time
of omalizumab prescription, six (75%) of the 6e11 year-olds
and two (33%) of the 12e17 year-olds. Loss of control
occurred in 9 (69.2%) of the 13 patients who had received
omalizumab for <1 year (median follow-up time: 16.8
months); 13 (59.1%) of the 22 patients who had been
treated for 1e2 years (median follow-up time: 10.3
months); and 12 (46.1%) of the 26 patients treated for >2
years (median follow-up time: 7.5 months).
The median time to loss of control after discontinuation
was 13.0 months (mean 20.4  2.6 months; 95% CI:
8.3e28.1). The criteria defining loss of control in the 34
patients were: an exacerbation requiring OCS, with control
not restored 1 month after the last dose of OCS, in 11
(32.3%); two exacerbations requiring OCS within 1 year in
Table 2 Omalizumab treatment.
Parameter Study population (n Z 61)
Duration of omalizumab
treatment (months)
Mean  SD [range]
22.7  13.1 [2.5e59.5]
6e11 years (n Z 8) 24.3  7.1 [13.0e36.6]
12e17 years (n Z 6) 24.7  10.1 [9.2e35.4]
18 years (n Z 47) 22.2  14.3 [2.5e59.5]
Dosage of omalizumab
(mg/month)
Mean  SD [range]
426  233 [75e900]
Duration of asthma control
before discontinuation
(months)
Mean  SD [range] MD
15.1  11.8 [0e56.2] 3
6e11 years (n Z 8) 17.9  7.9 [8.9e33.54]
12e17 years (n Z 6) 17.9  10.6 [0e29.9]
18 years (n Z 44) 14.1  12.57 [0e56.2]
Time free of exacerbations
prior to discontinuation
(months)
Mean  SD [range]
8.7  7.7 [0.2e30.1]
Global evaluation of treatment effectiveness at
discontinuation
- Excellent 52.5%
- Good 47.5%
Gain in FEV1 vs baseline
(% predicted)
Mean  SD [range] MD
13  20 [23 to 72] 8
Change in ICS dose vs baseline
(mg, BDP equivalent)
Mean  SD [range] MD
278  494 [1900 to 600] 2
BDP, beclomethasone dipropionate; FEV1, forced expiratory
volume (1 s); ICS, inhaled corticosteroid; MD, missing data; SD,
standard deviation.
Table 3 Loss of control and follow-up times.
Loss of control (n Z 61) 34 (55.7%)
- <1 year treatment (n Z 13) 9 (69.2%)
- 1e2 years’ treatment (n Z 22) 13 (59.1%)
- >2 years’ treatment (n Z 26) 12 (46.1%)
Follow-up time (n Z 61)
Median/mean  SD
9.3/12.1  9.8
- <1 year treatment (n Z 13) 16.8/17.8  11.8
- 1e2 years’ treatment (n Z 22) 10.3/12.5  11.2
- >2 years’ treatment (n Z 26) 7.5/8.9  5.5
Time-to loss of control (months)
Median/mean  SE
-Total population (n Z 34) 13.0/20.4  2.6
-‘Excellent’ response (n Z 17) 17.0/20.8  3.8
-‘Good’ response (n Z 17) 12.8/12.5  1.4
-<1 year treatment (n Z 13) 17.0/22.5  4.7
-1e2 years’ treatment (n Z 22) 12.8/11.2  1.5
->2 years’ treatment (n Z 26) 9.0/7.1  0.5
SD, standard deviation; SE, standard error.
Figure 1 Time to loss of control/follow-up censoring as a
function of the length of the course of omalizumab treatment.
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least 3 GINA criteria/increase in ACQ score >1.5/ACT score
<19) lasting at least 4 weeks in 11 (32.4%). Some patients
met more than one criterion for loss of control.
In the other 27 patients, asthma control was maintained
through to the end of their follow-up period. Thus, data are
available for all 61 patients at Month 5.4 after discontinu-
ation; by that time, loss of asthma control had occurred in
15. Between Month 5.4 and Month 12, loss of asthma control
was documented in a further 11 of the 46 patients still
under control at the beginning of that period. In the
remaining 35 patients, sustained control was documented
from Months 12e23; follow-up ended without loss of control
between 5.4 and 12 months in 12 patients. Only 6 patients
had >2 years of follow-up, and sustained control was
documented in four of these.
Time to loss of control was longer in the 32 patients with
an ‘excellent’ response (median: 17.0 months) compared
with the 29 patients with a ‘good’ response (median: 12.8
months); however, comparison of the survival curves for
these sub-groups (data not shown) did not detect any sta-
tistically significant effect. Time to loss of control/follow-
up censoring as a function of the length of the course ofomalizumab treatment is shown in Fig. 1. No early loss of
control (i.e. within 6 months following discontinuation) was
observed among patients with >3.5 years continuous
omalizumab treatment.
No effect on time to loss of control was detected in a
comparison of survival curves stratified on the basis of
duration of treatment, or in a univariate analysis of this
factor (data not shown). Additionally, no relationship was
detected between time to loss of control and either the
dosage administered or the duration of satisfactory control
before the discontinuation of omalizumab.Resumption of omalizumab
Of the 34 patients in whom asthma control was lost, 20
(58.8%) were re-prescribed omalizumab. Response to oma-
lizumab re-treatment was considered ‘excellent’ in 6 pa-
tients (30%) and ‘good’ in 8 patients (40%). Of the remaining
6 patients, 4 (20%) did not respond to re-treatment, and two
Discontinuation of omalizumab 575could not be assessed for response because the duration of
follow-up was too short.Discussion
This retrospective, observational study suggests that dis-
continuing omalizumab after control has been obtained in
patients with severe, persistent, allergic asthma is without
any rebound effect. Asthma control was lost in 34 patients
(55.7%) after a median period of 13 months following the
discontinuation of omalizumab. However, none of the pa-
tients with loss of asthma control within 6 months of
stopping treatment had been treated with omalizumab for
>3.5 years. This would suggest that the risk of early loss of
control is small after a long enough course of treatment.
The average duration of omalizumab treatment prior to
discontinuation was nearly 2 years, but the range was wide,
from just 10weeks to nearly 5 years. Similarly, very different
criteria were used by different physicians to define satis-
factory control on treatment, and there was wide variability
in the duration of omalizumab treatment once asthma was
controlled on treatment, from zero (i.e. treatment was
stopped as soon as control was established) to >4.5 years.
These observations illustrate the divergence in clinical
practice among respiratory specialists. This might be ex-
pected with a relatively new drug for which the prescribing
information is succinct, especially concerning discontinua-
tion criteria. In the present study, patients in whom the
response to omalizumab treatment had been judged as
excellent remained controlled, post-discontinuation, for
longer than those in whom response was judged as good
(median 17 versus 13 months, respectively). This might
indicate that degree of response while still on treatment is a
useful indicator of persistency of effect, although no sta-
tistically significant relationship was detected between time
to loss of control and either response on treatment, or
duration of satisfactory control before discontinuation of
omalizumab.
As well as the degree of response and its duration, many
other factors should be taken into account when deciding
whether to stop omalizumab treatment, including: the his-
tory of the severity of the disease; the need for other drugs,
together with their relative advantages and disadvantages
(notably OCS); adverse reactions; pregnancy; environmental
changes (e.g. the risk of parasitic infections); comorbidities
(notably, the impact of other allergic manifestations on
quality of life, and the effectiveness of omalizumab against
them); and patient preferences.
In more than 75% of patients who were re-treated with
omalizumab after asthma control was lost, responses to re-
treatment were judged as ‘excellent’ or ‘good‘, and four out
of 20 patients did not respond to omalizumab re-treatment.
However, in the absence of a control arm in which patients
did not discontinue omalizumab, we cannot exclude the
possibility that some patients could have experienced dete-
rioration of their condition despite continued treatment.
This real-life study has limitations. In particular,
because omalizumab has only been available in France
since 2006 for adults and adolescents and 2009 for children,
patients who received a longer course of treatment tended
to have a shorter follow-up. Our results suggest that loss ofasthma control following omalizumab discontinuation is
more likely in patients treated for a shorter length of time
(Table 3). However, the results are difficult to interpret,
because patients with shorter durations of treatment also
had longer follow-up times. It is possible that differences in
loss of asthma control would have been less pronounced, or
would have disappeared altogether, if the follow up times
had been the same for each of the treatment duration
subgroups. It is important to note that no delayed loss of
control (i.e. occurring >30 months after the discontinua-
tion of omalizumab) was observed in patients treated for
more than two years. However, this could be because the
follow-up period was too short. This study does not allow
any definitive answer on the optimum duration of omali-
zumab treatment. However, the results suggest that the
risk of early loss of control is small after a long enough
course of treatment.
Given the frequent reluctance of patients to embark on
any lifelong treatment, it is important for prescribing
physicians to be able to offer hope that discontinuation
might be possible under certain conditions. To date, there
have been no data from appropriately designed clinical
trials that would inform when to discontinue treatment.
Data from follow-up of the INNOVATE clinical study
showed that IgE levels climbed back up to pre-treatment
levels after the end of a 6-month course of treatment and
that this correlated with symptom score, back-up drug
consumption and impaired lung function [14]. However,
after discontinuation at the end of a 6-year course of
omalizumab, the beneficial effects of the treatment were
sustained through three years in 12 out of 18 members of a
cohort of cat-allergic Swedish patients [15], a long-term
effect which the authors ascribed to permanent desensiti-
sation of basophils, i.e. the interruption of a vicious cycle.
So, targeted clinical trials need to be performed to
establish evidence-based discontinuation criteria, notably
to define the optimum duration of treatment (especially in
the light of preliminary results suggesting that a sufficiently
long course of omalizumab may have a disease-modifying
effect [16]) and identify reliable predictors of sustained
control after discontinuation.
This could be remedied by the XPORT study
(NCT01125748), which is currently underway in the United
States, which investigates the impact of omalizumab with-
drawal on clinical outcomes over a 1-year period, following
successful 5 years of therapy. Results are expected during
2014. It may take some years to accumulate sufficient data
on outcomes in patients who have discontinued omalizumab
after extended courses of treatment, especially under real-
life prescription conditions. It inevitably takes time to
accumulate long-term data on a recently licensed drug, but
severe, treatment-refractory asthma is a major public
health problem, and efforts to collect such data are
warranted.
In conclusion, these data offer insights into the discon-
tinuation of successful omalizumab treatment in severe
asthmatic patients. In this real world setting, asthma con-
trol was maintained in about half of patients following
treatment discontinuation, particularly for the patients
who were on longer duration treatment. Discontinuation
was not associated with any rebound effect. Further studies
are needed to better define the criteria for omalizumab
576 M. Molimard et al.discontinuation, as this may help to reduce the risk of
subsequent loss of asthma control.
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